How to buy Vaxxinity stock (VAXX)

Vaxxinity is a biotechnology business based in the US. Vaxxinity shares (VAXX) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.00 – the same closing value as a week prior. Vaxxinity employs 57 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Vaxxinity stock

Buy Vaxxinity stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Vaxxinity stock price (PINK: VAXX)

Use our graph to track the performance of VAXX stocks over time.

Vaxxinity shares at a glance

• Key figures

Information last updated 2024-10-25.

Latest market close	$0.00
52-week range	$0.00 - $1.33
50-day moving average more info button	$0.02
200-day moving average more info button	$0.29
Wall St. target price	$15.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.45

Vaxxinity price performance over time

Historical closes compared with the close of $0.002 from 2024-10-25

1 week (2024-10-18)	0.002
1 month (2024-09-27)	-90.00%
3 months (2024-07-26)	-93.33%
6 months (2024-04-26)	-98.28%

1 year (2023-10-27)	-99.80%
2 years (2022-10-27)	-99.86%
3 years (2021-10-23)	N/A
5 years (2019-10-23)	N/A

Vaxxinity financials

Gross profit TTM	$-1,871,000
Return on assets TTM	-48.34%
Return on equity TTM	-150.65%
Profit margin	0%
Book value	$0.11
Market Capitalization more info button	$8.9 million

TTM: trailing 12 months

Vaxxinity share dividends

We're not expecting Vaxxinity to pay a dividend over the next 12 months.

You may also wish to consider:

• Pfizer (PFE.US) (5.82% forward annual dividend yield)
• AstraZeneca PLC ADR (AZN.US) (1.96% forward annual dividend yield)

Vaxxinity share price volatility

Over the last 12 months, Vaxxinity's shares have ranged in value from as little as $0 up to $1.33. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Vaxxinity's is 2.933. This would suggest that Vaxxinity's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put Vaxxinity's beta into context you can compare it against those of similar companies.

• Moderna (MRNA.US): 1.661
• Pfizer (PFE.US): 0.617
• AstraZeneca PLC ADR (AZN.US): 0.166

Vaxxinity overview

Vaxxinity, Inc. , a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida. .

Frequently asked questions

What percentage of Vaxxinity is owned by insiders or institutions?
Currently 50.707% of Vaxxinity shares are held by insiders and 0.158% by institutions. How many people work for Vaxxinity?
Latest data suggests 57 work at Vaxxinity. When does the fiscal year end for Vaxxinity?
Vaxxinity's fiscal year ends in December. Where is Vaxxinity based?
Vaxxinity's address is: 505 Odyssey Way, Merritt Island, FL, United States, 32953 What is Vaxxinity's ISIN number?
Vaxxinity's international securities identification number is: US92244V1044